By Hendra Lukman 
Stanford Medicine researchers have achieved a significant breakthrough in the fight against Type 1 diabetes, demonstrating in preclinical studies that a novel approach involving the transplantation of both blood-forming stem cells and pancreatic islet cells from immunologically mismatched donors can completely prevent or fully reverse the disease in mice. This pioneering strategy, detailed in a recent publication, holds immense promise for transforming the treatment landscape for individuals living with this chronic autoimmune condition.
The core of this groundbreaking research lies in the creation of a "hybrid immune system" within the recipient animals. This innovative method circumvents the body’s own immune system, which in Type 1 diabetes, mistakenly targets and destroys the insulin-producing islet cells in the pancreas. Crucially, the study reports that none of the treated mice developed graft-versus-host disease (GvHD), a serious complication where the donor’s immune cells attack the recipient’s healthy tissues. Furthermore, the destruction of islet cells by the animals’ original immune system ceased, and remarkably, the mice no longer required immunosuppressive drugs or insulin for the entire six-month duration of the study.
A Paradigm Shift in Autoimmune Disease Management
The implications of this research are profound, offering a potential cure rather than just management for Type 1 diabetes. Dr. Seung K. Kim, the KM Mulberry Professor and a leading figure in developmental biology, gerontology, endocrinology, and metabolism at Stanford Medicine, expressed significant optimism about the findings. "The possibility of translating these findings into humans is very exciting," Dr. Kim stated. He highlighted that the critical steps in their study, which lead to the establishment of a hybrid immune system comprising cells from both donor and recipient, are already in clinical use for other medical conditions. This suggests a potentially accelerated pathway to human trials.
Dr. Kim, who also directs the Stanford Diabetes Research Center and the Northern California Breakthrough T1D Center of Excellence, believes this approach could be "transformative" not only for individuals with Type 1 diabetes and other autoimmune diseases but also for those requiring solid organ transplants. The research, with graduate and medical student Preksha Bhagchandani as the lead author, was published online on November 18th in the prestigious Journal of Clinical Investigation.
Building on a Foundation of Stem Cell and Islet Research
This latest study represents a significant advancement building upon earlier work by Dr. Kim and his collaborators. In a 2022 study, the team had successfully restored blood sugar control in mice that had been induced into diabetes. That earlier research involved a gentler pre-transplant preparation using immune-targeting antibodies and low-dose radiation, followed by a transplant of blood stem cells and islet cells from an unrelated donor. However, the 2022 study focused on overcoming immune rejection of donor islets in a model of induced diabetes, not the spontaneous autoimmune attack characteristic of Type 1 diabetes in humans.
The current research tackled a far more formidable challenge: preventing or curing diabetes driven by the body’s own autoimmune response. In Type 1 diabetes, the immune system spontaneously targets and destroys the insulin-producing beta cells within the pancreatic islets. Unlike the induced-diabetes model where the primary obstacle was recipient immune rejection of donor islets, the new model presented a dual threat. The transplanted islets were not only recognized as foreign tissue but were also subjected to an immune system already predisposed to attacking islet cells from any source.
"Just like in human Type 1 diabetes, the diabetes that occurs in these mice results from an immune system that spontaneously attacks the insulin-producing beta cells in pancreatic islets," explained Dr. Kim. "We need to not only replace the islets that have been lost but also reset the recipient’s immune system to prevent ongoing islet cell destruction. Creating a hybrid immune system accomplishes both goals."
A Refined Protocol for Robust Immune Tolerance
A key hurdle in applying blood stem cell transplants to autoimmune conditions is that the very biological traits that drive autoimmunity can also make recipients more susceptible to complications during the pre-transplant preparation. The Stanford team, however, identified a remarkably straightforward solution.
By incorporating a medication commonly used in the treatment of autoimmune diseases into their existing pre-transplant regimen—a protocol that had been refined in their 2022 study—they achieved remarkable success. This adjusted protocol, followed by the combined blood stem cell and islet cell transplantation, led to the development of a hybrid immune system composed of cells from both the donor and the recipient. In a striking demonstration of efficacy, 19 out of 19 mice in this group did not develop Type 1 diabetes. Even more compelling, in a separate cohort of mice that already had long-standing Type 1 diabetes, nine out of nine experienced a complete cure following the combined transplant.
The significance of this drug adjustment lies in its accessibility. The antibodies, drugs, and low-dose radiation employed in the mice are already standard components of clinical practice for blood stem cell transplantation. This existing familiarity with the therapeutic agents and procedures significantly bolsters the researchers’ confidence in moving this strategy towards human clinical trials for Type 1 diabetes.
The Legacy of Hybrid Immunity and the Future of Transplants
This innovative approach to Type 1 diabetes treatment is deeply rooted in decades of research into immune tolerance, particularly work led by the late Samuel Strober, MD, PhD, a distinguished professor of immunology and rheumatology at Stanford, and his colleagues. Their seminal research demonstrated that bone marrow transplants from partially immunologically matched human donors could induce a hybrid immune system in recipients, facilitating long-term acceptance of kidney transplants from the same donor. In some patients, this led to stable kidney function for decades without the need for continuous immunosuppressive drugs.
Blood stem cell transplants are already a well-established treatment for various blood cancers, including leukemia and lymphoma. However, these procedures typically involve high doses of chemotherapy and radiation to eradicate the patient’s existing blood and immune system, often leading to severe side effects. Dr. Judith Shizuru, a professor of medicine and co-author on the current study, along with her colleagues, has been instrumental in developing safer, less intensive pre-transplant conditioning protocols for non-cancerous conditions. Their goal has been to prepare patients for donor blood stem cell transplantation by reducing bone marrow activity just enough to allow donor stem cells to engraft and proliferate, thereby minimizing toxicity.
"Based on many years of basic research by us and others, we know that blood stem cell transplants could also be beneficial for a wide range of autoimmune diseases," Dr. Shizuru commented. "The challenge has been to devise a more benign pre-treatment process, diminishing risk to the point that patients suffering from an autoimmune deficiency that may not be immediately life-threatening would feel comfortable undergoing the treatment."
The current research directly addresses this challenge. "Now we know that the donated blood stem cells re-educate the recipient animal’s immune system to not only accept the donated islets, but also not attack its healthy tissues, including islets," Dr. Kim explained. "In turn, the donated blood stem cells and the immune system they produce learn to not attack the recipient’s tissues, and graft-versus-host disease can be avoided." This bidirectional immune tolerance is the cornerstone of the study’s success.
Navigating Future Hurdles and Expanding Horizons
Despite the highly encouraging results in mice, the path to widespread clinical application for Type 1 diabetes treatment involves several significant obstacles. A primary challenge is the current scarcity of suitable pancreatic islets, which are exclusively obtained from deceased donors. Furthermore, the blood stem cells must originate from the same individual as the islets. The question also remains whether the typical number of islet cells recovered from a single donor would consistently be sufficient to reverse established Type 1 diabetes in human patients.
The Stanford research team is actively exploring innovative solutions to these limitations. These include the development of methods to generate large quantities of islet cells in the laboratory from pluripotent human stem cells, a field that has seen rapid advancements in recent years. Additionally, researchers are investigating techniques to enhance the survival and functionality of transplanted donor islets after transplantation.
Beyond the realm of Type 1 diabetes, Dr. Kim, Dr. Shizuru, and their colleagues are optimistic that their gentle pre-conditioning strategy could pave the way for stem cell transplants for a broader spectrum of autoimmune diseases. Conditions such as rheumatoid arthritis and lupus, as well as non-cancerous blood disorders like sickle cell anemia—for which current blood stem cell transplant methods remain particularly harsh—could potentially benefit from this refined approach. Moreover, the strategy holds promise for transplants involving mismatched solid organs, a long-standing goal in transplantation medicine.
"The ability to reset the immune system safely to permit durable organ replacement could rapidly lead to great medical advances," Dr. Kim concluded, underscoring the transformative potential of this research.
The study was supported by substantial funding from the National Institutes of Health (grants T32 GM736543, R01 DK107507, R01 DK108817, U01 DK123743, P30 DK116074, and LAUNCH 1TL1DK139565-0), the Breakthrough T1D Northern California Center of Excellence, Stanford Bio-X, the Reid Family, the H.L. Snyder Foundation and Elser Trust, the VPUE Research Fellowship at Stanford, and the Stanford Diabetes Research Center. This multi-faceted support highlights the collaborative and resource-intensive nature of such groundbreaking scientific endeavors.